Article Text

PDF
A8.9 Neutralisation of miR-155 ameliorates collagen-induced arthritis
  1. BE Morton1,
  2. S Neben2,
  3. N Gibson2,
  4. C McSharry1,
  5. IB McInnes1,
  6. M Kurowska-Stolarska1
  1. 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
  2. 2Regulus Therapeutics, San Diego, CA, USA

Abstract

Background and objectives Elevated miR-155 expression levels mediate adaptive and inflammatory events in Rheumatoid Arthritis by inhibiting the translation of key mRNAs involved in germinal centre and anti-inflammatory signalling. miR-155-deficient mice are protected from collagen-induced arthritis due to impaired auto-antibody production, Th17 differentiation and macrophage activation. However, active miR regulation as a therapeutic modality has not been attempted in arthritis models before and is a critical next step towards evaluating the translational potential of these pathways. We therefore investigated active neutralisation of miR-155 using in vitroand in vivo models with a novel miR-155 inhibitor.

Materials and methods For in vitro experiments, bone marrow was isolated from wild-type mice and differentiated into macrophages with M-CSF (50 ng/ml) for 6 days. Mature macrophages were transfected with miR-155 inhibitor (125, 250 or 500 nM; Regulus) or control inhibitor 24 h before stimulation with LPS (10 ng/ml). TNF-α production was measured by ELISA 24 h post-stimulation. miR-155 levels were measured by RT-qPCR. In vivo, CIA was induced using type II collagen with Complete Freund’s Adjuvant on day 1, and re-challenging with collagen on day 21. Mice were treated therapeutically with miR-155 inhibitor, control inhibitor or PBS on days 22, 29, 36 and 41 at the dose of 25 mg/kg. Clinical changes were scored every second day and concentration of serum IgG anti-collagen antibodies measured by ELISA.

Results Treatment of macrophages with miR-155 inhibitor significantly reduced TNF-α production in response to LPS (p = 0.007; n = 3 experiments), across a range of inhibitor concentrations. The therapeutic treatment with miR-155 inhibitor in vivo ( n = 12 mice/group) reduced onset of CIA and significantly reduced the severity of arthritis compared to control inhibitor at day 42 (clinical score 5.1+/-1.8mm versus 2.3+/-0.9mm, p < 0.001). There was no difference between control inhibitor and miR-155 inhibitor treatment in levels of anti-collagen antibodies.

Conclusions These experiments highlight the therapeutic potential of a miR-155 inhibitor to ameliorate severity of CIA in vivo. The in vitro mechanistic data demonstrates that the anti-inflammatory effect occurs inhibition of macrophage TNF-α production in response to LPS stimulation. The therapeutic effect of miR-155 inhibition during the effector phase of arthritis provides proof-of-concept that miR-155 is crucial in driving articular inflammation.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.